Biomea Fusion completes enrollment in Phase II diabetes trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Biomea Fusion completes enrollment in Phase II diabetes trial

Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

August 24, 2026 7:00 AM EDT

Topline 26-week primary endpoint data from COVALENT-211 in insulin deficient type 2 diabetes (T2D) patients who are not achieving glycemic targets despite antihyperglycemic medications anticipated in the first quarter of 2027COVALENT-212 Phase II enrollment T2D patients who are not achieving glycemic targets despite GLP-1 based therapy is still ongoing, with topline 26-week primary endpoint data anticipated in the second quarter of 2027These ongoing Phase II diabetes trials target two distinct T2D populations that... More